Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD9750 · 1 trial · 1 indication
To evaluate the safety and tolerability and determine the MTD and/or the RDE(s)/RP2D of AZD9750 as a monotherapy and in combination with other anticancer agents in participants with mCRPC. A DLT is a toxicity defined by the study protocol that occurs from the first dose of study intervention up to the end of the DLT evaluation period that is assessed as clearly unrelated to the primary disease or intercurrent illness.
The number of participants with adverse events and with serious adverse events will be assessed.
The number of participants with clinically significant changes from baseline in vital signs will be assessed.
The number of participants with clinically significant changes from baseline in vital signs will be assessed.
The number of participants with clinically significant changes from baseline in physical examination will be assessed.
The number of participants with clinically significant changes from baseline in ECOG PS will be assessed.
The number of participants with clinically significant changes from baseline in ECGs will be assessed.
The number of participants with clinically significant changes from baseline in laboratory parameters will be assessed.
To evaluate the preliminary antitumour efficacy of AZD9750 as monotherapy and in combination with other anticancer agents in participants with mCRPC.
| Arm | Type | Description |
|---|---|---|
| Module 1 / Part A1 | EXPERIMENTAL | AZD9750 Monotherapy (Dose Escalation) - No randomization |
| Module 1 / Part A2 | EXPERIMENTAL | AZD9750 Monotherapy (Backfills) - No randomization |
| Module 1 / Part B1 | EXPERIMENTAL | AZD9750 Monotherapy (Dose Optimization) - Randomization |
| Module 1 Part B2 | EXPERIMENTAL | AZD9750 Monotherapy (Dose Expansion) - No randomization |
| Module 1 / Part B3 | EXPERIMENTAL | AZD9750 Monotherapy (Dose Expansion) - No randomization |
| Module 2 / Part A | EXPERIMENTAL | AZD9750 + Saruparib (Combination Dose Finding) - No Randomization |
| Module 2/ Part B | EXPERIMENTAL | AZD9750 + Saruparib (Combination Dose Expansion) - No Randomization |
| Name | Type | Description |
|---|---|---|
| AZD9750 | DRUG | AR-PROTAC |
| AZD5305 | DRUG | PARP1-selective inhibitor |
* Inclusion Criteria: * Participant must be ≥18 years or the legal age at the time of signing the informed consent form. * Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate. * Documented metastatic disease. * Serum testosterone levels ≤ 50 ng/dL. * Evid...
Top 20 of 53 competitors
AZD9750 is an investigational small molecule being studied for the treatment of metastatic prostate cancer. It is currently in Phase 1 clinical development, where it is being evaluated for safety and effectiveness when given alone or with other anticancer drugs.
The specific molecular target of AZD9750 has not been disclosed. It is a small molecule oncology drug, but its mechanism of action is not publicly detailed in the available clinical trial information.
AZD9750 is being developed by AstraZeneca PLC, a global biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting a Phase 1 trial to evaluate the drug in patients with metastatic prostate cancer.
AZD9750 is in Phase 1 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is currently being tested in a Phase 1 trial to assess its safety, tolerability, and preliminary efficacy in metastatic prostate cancer.
AZD9750 is being studied in a Phase 1 clinical trial with the identifier NCT07336446. This trial is recruiting male patients aged 18 years and older with metastatic prostate cancer, and it is being conducted in the United States, Australia, Canada, China, Japan, Netherlands, Spain, and the United Kingdom.